- In 2023, Acacia Pharma introduced Barhemsys and Amisulpride as primary antiemetics for managing PONV. Barhemsys, an intravenous selective dopamine D2 and D3 receptor antagonist, effectively prevents and treats PONV, gaining regulatory approval in the US and Europe for its high efficacy
- In 2023, Roche developed a patient-controlled analgesia (PCA) system for PONV. This system administers opioids and antiemetics via a pump, significantly reducing PONV incidence and enhancing patient satisfaction
Frequently Asked Questions
The market is segmented based on Global Postoperative Nausea and Vomiting Treatment Market Segmentation, By Treatment Type (Serotonin Receptor Antagonists, Steroids, Dopamine Antagonists, Neurokinin NK-1 Receptor Antagonists, and Non-pharmacological Treatment), Application (Postoperative Nausea and Vomiting (PONV), Chemotherapy-Induced Nausea and Vomiting (CINV), Motion Sickness, Pregnancy, and Others), End-Users (Clinic, Hospital, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) – Industry Trends and Forecast to 2031
.
The Global Postoperative Nausea And Vomiting Treatment Market size was valued at USD 2.19 USD Billion in 2023.
The Global Postoperative Nausea And Vomiting Treatment Market is projected to grow at a CAGR of 5.52% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
